Lexeo Therapeutics (LXEO) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ocugen (OCGN) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 33.8% versus a loss of 67.3%. Ocugen is the larger company by market cap ($260.6 million vs $245.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | OCGN |
|---|---|---|
| Share price | $2.96 | $0.7679 |
| Market cap | $245.05M | $260.55M |
| 1-day change | +0.34% | +4.79% |
| YTD return | -70.19% | -43.12% |
| 1-year return | -67.33% | -33.80% |
| 5-year return | — | -88.09% |
| EPS (TTM) | $-1.13 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.41M |
| Revenue growth (YoY) | — | +8.83% |
| Net income (latest FY) | $-100.00M | $-67.85M |
| Operating margin | — | -1425.70% |
| Net margin | — | -1537.41% |
| 52-week high | $10.99 | $2.73 |
| 52-week low | $2.55 | $0.691 |
| Distance from 52-week high | -73.07% | -71.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +748.31% | +1484.84% |
| Average volume | 1.98M | 7.34M |
| Shares outstanding | 82.79M | 339.31M |
| Employees | 68 | 116 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OCGN has outperformed LXEO by 33.5 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
LXEO vs OCGN FAQ
Which is bigger, Lexeo Therapeutics or Ocugen?
Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $245.05M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, LXEO or OCGN?
OCGN returned -33.80% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.